Human trials of Russia’s second potential coronavirus vaccine, developed by the Siberian Vector institute, will begin on July 27, Reuters reported citing Russian news agency TASS.
An early-stage human trial of a separate vaccine, developed by the Gamaleya Institute in Moscow, was completed this month, with scientists hailing the results and authorities planning to move to mass production in the autumn.